Daunorubicin, Cytarabine Liposomes Plus Venetoclax vs Azacitidine Plus Venetoclax in AML Patients Unfit for Intensive Chemotherapy

NCT06770257 | Withdrawn Phase 2

• 1 other identifier: IIT2024082
• Study Type: interventional
• Target: N/A
• Locations: 0 countries
• Sites: N/A

Brief Summary

Daunorubicin, Cytarabine Liposomes(CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.) is a dual-drug liposomal encapsulation of cytarabine and daunorubicin at a fixed 5:1 synergistic molar ratio. This is a phase 2, randomized, controlled study in patients who are \>= 18 or more years old and have not been treated before. Participants who take part in this study should not be suitable for intensive induction therapy. In this study, patients will be randomized by 1:1:1 to receive Daunorubicin, Cytarabine Liposomes + Venetoclax(14d) or Daunorubicin, Cytarabine Liposomes + Venetoclax(21d) or Venetoclax + Azacitidine. Participants will continue to have study visits and receive treatment for as long as they are having a clinical benefit.

Conditions

Leukemia, Myeloid, Acute

Outcome Measures

Primary Outcomes (1)

• Complete remission rate(CR)

  Proportion of patients with complete remission during the treatment period.

  Up to 8 months

Secondary Outcomes (4)

• Composite complete remission rate(cCR)

  Up to 8 months

• Proportion of pateints who achieve Measurable residual disease（MRD） negativity

  Up to 8 months

• Event-free survival (EFS)

  Up to 2 years

• Overall survival (OS)

  Up to 2 years

Study Arms (3)

ArmA（daunorubicin, cytarabine liposomes plus 14d-venetolcax）

EXPERIMENTAL

Patients receive daunorubicin, cytarabine liposomes through intravenous injection(IV) on days 1、3、5, and venetoclax orally（PO） daily on days 1-14. Treatment repeats every 28 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity.

Drug: daunorubicin, cytarabine liposomes; Drug: Venetoclax

ArmB（daunorubicin, cytarabine liposomes plus 28d-venetolcax）

EXPERIMENTAL

Patients receive daunorubicin, cytarabine liposomes IV on days 1、3、5, and venetoclax PO daily on days 1-28. Treatment repeats every 28 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity.

Drug: daunorubicin, cytarabine liposomes; Drug: Venetoclax

ArmC（azacitidine plus 28d-venetoclax）

ACTIVE COMPARATOR

Patients receive azacitidine subcutaneously (SC) on days 1-7, and venetoclax PO daily on days 1-28. Treatment repeats every 28 days for up to 8 cycles in the absence of disease progression or unacceptable toxicity.

Drug: Azacitidine; Drug: Venetoclax

Interventions

daunorubicin, cytarabine liposomes DRUG

First induction: 100 units/m\^2 by 90-minute IV infusion on Days 1, 3, 5. Second induction: 100 units/m\^2 by 90-minute IV infusion on Days 1 and 3. Consolidation therapy: 65 units/m\^2 by 90-minute IV infusion on Days 1 and 3.

ArmA（daunorubicin, cytarabine liposomes plus 14d-venetolcax）; ArmB（daunorubicin, cytarabine liposomes plus 28d-venetolcax）

Azacitidine DRUG

Given SC on days 1-7

ArmC（azacitidine plus 28d-venetoclax）

Venetoclax DRUG

Given PO on days 1-14 or 1-21 or 1-28

ArmA（daunorubicin, cytarabine liposomes plus 14d-venetolcax）; ArmB（daunorubicin, cytarabine liposomes plus 28d-venetolcax）; ArmC（azacitidine plus 28d-venetoclax）

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Participant must have confirmation of Acute Myeloid Leukemia (AML) by 2022 World Health Organization (WHO) criteria, previously untreated.
• Participant must be \>= 18 years of age.
• Participant must have a projected life expectancy of at least 12 weeks.
• Participant must be considered ineligible for intensive induction therapy defined by the following:
• a. \>= 75 years of age; b. \>= 18 to 74 years of age with at least one of the following comorbidities: i. Eastern Cooperative Oncology Group (ECOG) Performance Status of 2 or 3; ii. Cardiac history of Congestive Heart Failure (CHF) requiring treatment or Ejection Fraction \<= 50% or chronic stable angina; iii. Diffusing capacity of the Lung for Carbon Monoxide (DLCO) \<= 65% or Forced Expiratory Volume in 1 second (FEV1) \<= 65%; iv. Creatinine clearance \>= 30 mL/min to \< 45 ml/min; v. Moderate hepatic impairment with total bilirubin \> 1.5 to \<= 3.0 × Upper Limit of Normal (ULN); vi. Any other comorbidity that the physician judges to be incompatible with intensive chemotherapy.
• Participant must have an ECOG Performance status:
• to 2 for Participants \>= 75 years of age or 0 to 3 for Participants \>= 18 to 74 years of age. 6.Laboratory values meet the following criteria:
• Serum alanine aminotransferase or aspartate aminotransferase≤3 × ULN, ≤5 × ULN for patients with liver involvement.
• For participants of ≥ 75 years old: Serum total bilirubin≤1.5 × ULN, ≤3 × ULN for patients with liver involvement
• For participants of 18 to 74 years old: Serum total bilirubin≤ 3× ULN
• Adequate renal function as demonstrated by a creatinine \>= 30 mL/min; calculated by the Cockcroft Gault formula or measured by 24 hours urine collection.
• Male participants who are sexually active, must agree, from Study Day 1 through at least 6 months after the last dose of study drug, to practice the protocol specified contraception and agree to refrain from sperm donation during this period.
• Female participants of childbearing potential must practice the protocol specified contraception from Study Day 1 through at least 6 months after the last dose of study drug. Female participants must agree to refrain from preganancy, breastfeeding or egg donation during this period. Female participants of childbearing potential must have negative results for pregnancy test performed: At Screening with a serum sample obtained within 7 days prior to the first study drug administration.
• Participant must able to understand the study and voluntarily sign informed consent.

You may not qualify if:

• White blood cell count\>25 × 10 \^ 9/L (treatment with hydroxyurea or leukocyte isolation is allowed);
• Acute promyelocytic leukemia (APL);
• Previously received treatment with vinaclor or demethylating drugs or other chemotherapy drugs for AML or MDS (excluding the use of hydroxyurea before study administration)
• AML participants with good cytogenetic characteristics, including T (8; 21)/RUNX1:: RUNX1T1 or inv16/CBFB:: MYH11；
• AML secondary to MPN (including myelofibrosis, polycythemia vera, primary thrombocytosis, CML) and accompanied by BCR: AML participants of ABL1;
• AML participants with known central nervous system involvement;
• Within 6 months prior to the first administration, there is active cardiovascular disease, including but not limited to the following conditions: myocardial infarction, unstable angina, uncontrolled arrhythmia, and grade III/IV heart failure (New York Heart Association standard, NYHA); Hypertension that is still poorly controlled after antihypertensive treatment (with three consecutive measurements of systolic blood pressure ≥ 160mmHg and/or diastolic blood pressure ≥ 90mmHg during the screening period).
• hepatitis B B surface antigen (HBsAg) positive/hepatitis B B core antibody (HBcAb) positive, HBV DNA higher than the measurable lower limit or 1000 copies/mL (500IU/mL) (whichever is lower), HCV antibody positive and HCV RNA higher than the measurable lower limit or 1000 copies/mL (whichever is lower);
• History of immunodeficiency, including positive HIV antibody test;
• Have used other clinical trial drugs for treatment within one month before receiving treatment;
• Participants who received potent or moderate cytochrome P450 3A (CYP3A) inducers/inhibitors or P-glycoprotein (P-gp) inhibitors within 7 days prior to commencing study treatment;
• Participants have consumed grapefruit, grapefruit products, Seville oranges (including jam containing Seville oranges), or starfruit within 3 days prior to the first administration of the study drug.
• Have a history of allergic reactions to the ingredients of the research drug (and its excipients) and/or other similar products;
• Wilson's disease history or other history of copper metabolism abnormalities;
• Participants with cumulative exposure to anthracycline drugs exceeding 339 mg/m2 of daunorubicin (or equivalent drug dose level);

Sponsors & Collaborators

• Institute of Hematology & Blood Diseases Hospital, China: lead
• CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.: collaborator

MeSH Terms

Conditions

Leukemia, Myeloid, Acute

Interventions

Daunorubicin; Azacitidine; venetoclax

Condition Hierarchy (Ancestors)

Leukemia, Myeloid; Leukemia; Neoplasms by Histologic Type; Neoplasms; Hematologic Diseases; Hemic and Lymphatic Diseases

Intervention Hierarchy (Ancestors)

Anthracyclines; Naphthacenes; Polycyclic Aromatic Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydrocarbons; Organic Chemicals; Polycyclic Compounds; Aminoglycosides; Glycosides; Carbohydrates; Aza Compounds; Cytidine; Pyrimidine Nucleosides; Pyrimidines; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Nucleosides; Nucleic Acids, Nucleotides, and Nucleosides; Ribonucleosides

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 7, 2025
• First Posted: January 13, 2025
• Study Start: December 10, 2025
• Primary Completion (Estimated): December 10, 2026
• Study Completion (Estimated): June 10, 2027
• Last Updated: June 3, 2025

Record last verified: 2024-12